Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Xenon-129 MRI in COPD patients receiving endobronchial valve therapy
NCT05433961Phase 1Terminated
- Sponsor
- Xemed
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperpolarized xenon gas, sponsored by Xemed. Primary endpoint: Lung function changes from baseline to follow-up as measured with hyperpolarized xenon MRI at 90 days. Started Oct 2023; status: terminated.
02
Drugs
hyperpolarized xenon gas
Beyond the preview
Go deeper on NCT05433961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433961.